MAP2K7 and metastatic melanoma: In conclusion, the analyses derived from different clinical studies indicate that combined B-Raf inhibition plus MEK inhibition improves efficacy compared to B-Raf inhibition alone for the treatment of advanced/metastatic melanoma harboring the BRAF V600 mutation, with three different combinations approved by the FDA (see above).